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First-trimester ultrasound measurements
and maternal serum biomarkers as
prognostic factors in monochorionic twins:
a cohort study
Fiona L. Mackie1,2*, Rebecca Whittle3, R. Katie Morris1,2, Jon Hyett4, Richard D. Riley3 and Mark D. Kilby1,2
Abstract
Background: Monochorionic twin pregnancies are at high risk of adverse outcomes, but it is not possible to
predict which pregnancies will develop complications. The aim of the study was to evaluate, in monochorionic
twin pregnancies, whether first-trimester ultrasound (nuchal translucency [NT], crown-rump length [CRL]), and
maternal serum biomarkers (alpha-fetoprotein [AFP], soluble fms-like tyrosine kinase-1 [sFlt-1] and placental growth
factor [PlGF]), are prognostic factors for fetal adverse outcome composite, twin-twin transfusion syndrome (TTTS),
growth restriction, and intrauterine fetal death (IUFD).
Methods: A cohort study of 177 monochorionic diamniotic twin pregnancies. Independent prognostic ability of
each factor was assessed by multivariable logistic regression, adjusting for standard prognostic factors. Factors were
analysed as continuous data; thus, the reported ORs relate to either 1% change in NT or CRL inter-twin percentage
discordance or one unit of measure in each serum biomarker.
Results: The odds of the fetal adverse outcome composite were significantly associated with increased NT inter-
twin percentage discordance (adjusted OR 1.03 [95% CI 1.01, 1.06]) and CRL inter-twin percentage discordance
(adjusted OR 1.17 [95% CI 1.07, 1.29]). TTTS was significantly associated with increased NT discordance (adjusted OR
1.06 [95% CI 1.03, 1.10]) and decreased PlGF (adjusted OR 0.42 [95% CI 0.19, 0.93]). Antenatal growth restriction was
significantly associated with increased CRL discordance (adjusted OR 1.20 [95% CI 1.08, 1.34]). Single and double
IUFD were associated with decreased PlGF (adjusted OR 0.34 [95% CI 0.12, 0.98]) and (adjusted OR 0.18 [95%CI 0.05,
0.58]) respectively.
Conclusion(s): This study has identified potential individual prognostic factors in the first trimester (fetal biometric
and maternal serum biomarkers) that show promise but require further robust evaluation in a larger, prospective
series of MC twin pregnancies, so that their usefulness both individually and in combination can be defined.
Trial registration: ISRCTN 13114861 (retrospectively registered)
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Background
Multiple pregnancies are at increased risk of adverse
outcome with twin perinatal mortality up to sevenfold
higher compared to singleton pregnancies [1] with
monochorionic diamniotic (MCDA) twins being at
higher risk of pregnancy loss and morbidity compared to
dichorionic twins [2]. These higher risks are secondary
to the presence of inter-twin anastomoses joining the
fetal circulations within the monochorionic (MC) pla-
centa [3] and subsequently increasing the risk of
twin-twin transfusion syndrome (TTTS) and fetal
growth restriction (FGR) (either one or both fetuses af-
fected) [4]. International guidelines recommend inten-
sive antenatal surveillance to detect adverse outcomes
complicating MC twins, principally TTTS and FGR.
This involves regular monitoring via ultrasound scans
from 16 weeks gestation at two weekly intervals to evalu-
ate the liquor volume in each fetal sac, fetal biometry,
and often fetoplacental Doppler assessment [5–8]. Such
obstetric surveillance requires ultrasonographic expertise
and health economic resources, it is time-consuming
and targets all MC twins as a ‘high-risk population’.
Additionally, this intensive surveillance may increase
maternal anxiety and affect mental health. If it was pos-
sible to predict which MC twin pregnancies were at
higher risk of developing complications, it would allow
clinicians to stratify care, and those at higher risk could
undergo more frequent surveillance, or be assessed earl-
ier in a tertiary referral centre. This does have financial
implications but may prevent fetal death as TTTS is a
highly morbid and rapidly progressive condition, and even
with current surveillance every 2 weeks, fetuses still die
before FLA. Identifying high-risk pregnancies may enable
the development of new therapies and prophylactic treat-
ments that at present are not possible. Other benefits of
prognostic factor research are that it informs adjustment
in observational studies and stratification within random-
isation of trials and provides the components of multivari-
able prognostic models [9, 10].
There has been interest in whether the risk of fetal dis-
ease of placental origin in singleton pregnancies could be
predicted using fetal biometry combined with maternal
biomarkers. The focus has been on circulating biochem-
ical markers such as those utilised in first-trimester com-
bined screening [11], i.e. pregnancy-associated plasma
protein A (PAPP-A) and free β-human chorionic gonado-
trophin (βhCG), but has also included alpha-fetoprotein
(AFP) and factors related to angiogenesis and vasculogen-
esis such as placental growth factor (PlGF) and soluble
fms-like tyrosine kinase-1 (sFlt-1). The evaluation of
first-trimester ultrasound measurements in MCDA twins
has noted that discordance in nuchal translucency (NT)
and crown-rump length (CRL) have demonstrated rela-
tively low sensitivity (~ 40%) and specificity (~ 60%) for
the prediction of adverse pregnancy outcomes, particularly
for TTTS [12–15].
Before developing multivariable risk prediction tools, it is
essential to identify prognostic factors (predictors) that can
be incorporated within the model. This requires prognostic
factor research [9, 10]. In MCDA twins complicated by
untreated TTTS, we have demonstrated that the
second-trimester maternal serum concentrations of AFP and
the ratio of sFlt-1 to PlGF were significantly higher in TTTS
compared to gestationally matched uncomplicated MCDA
twins [16, 17]; however, there has been little research on the
prognostic ability of first-trimester maternal serum [18].
This paper examines the prognostic ability of
first-trimester ultrasound biometry and maternal serum
biomarkers for adverse outcome in MC twin pregnan-
cies. We hypothesise that, in those with at higher risk,
NT, CRL, AFP, and sFlt-1 will be increased, and PlGF
will be decreased in the first trimester, preceding the
clinical features associated with adverse outcome, and
thus may be important prognostic factors.
Methods
This work is part of a larger study which was registered
in April 2016: ISRCTN 13114861 (www.isrctn.com/
ISRCTN13114861). The protocol was published prior to
analysis [19]. Since submitting the protocol for publica-
tion, a collaboration with the Royal Prince Alfred Hos-
pital, Sydney, Australia, was formed to generate a
multicentre, international cohort.
Participants
All women with a MCDA twin pregnancy who had under-
gone first-trimester aneuploidy screening in the West
Midlands and North Thames Regions, UK (October 2014
to September 2015), or at the Royal Prince Alfred Hospital,
Sydney (June 2011 to April 2016), had maternal serum
stored with consent at − 80 °C. Chorionicity was deter-
mined by first-trimester ultrasound noting a single placen-
tal mass, thin inter-twin membrane, and the presence of
the ‘T’ sign [20]. Pregnancies were prospectively dated using
the largest twin CRL between 45 and 84mm [5]. Women
had prenatal care at 29 different secondary and tertiary care
maternity units. Pregnancies were not eligible for inclusion
if they were concordant or discordant for structural fetal
anomalies, monoamniotic, higher-order multiples, or suf-
fered a fetal loss < 14weeks. Pregnancies were cared for ac-
cording to local and international guidelines. Prospectively
recorded outcome data until hospital discharge were retro-
spectively collected from the hospital notes.
Prognostic factor measurements
The biomarkers to be examined for their prognostic
ability were identified a priori, i.e. pre-defined before
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data collection and analysis to avoid data dredging and
selective reporting.
Ultrasound measurements
NT and CRL were performed using standard practice
(Fetal Anomaly Screening Programme [FASP] or Fetal
Medicine Foundation [FMF] protocols with UK National
External Quality Service [NEQAS] quality assessment)
in women who consented to first-trimester aneuploidy
screening [21, 22]. NT discordance (%) was calculated as
the smallest NT subtracted from the largest NT, divided
by the largest NT, and multiplied by 100. CRL discord-
ance (%) was calculated as per NT discordance. These
measurements were treated as continuous data within
analyses, and so, no cut-offs were applied [23].
Biomarker measurements
Three serum biomarkers (AFP, sFlt-1, PlGF) were mea-
sured on stored maternal serum samples that were ini-
tially analysed for β-hCG and PAPP-A as part of
aneuploidy screening and were subsequently stored at −
80 °C (between 4months and 5 years). The sFlt-1 and
PlGF assays were performed in a single batch at the Bio-
chemistry Department at University Hospital Birming-
ham, using the assay approved by the UK’s National
Institute for Health and Care Excellence (NICE) for rul-
ing out pre-eclampsia (Roche Diagnostics Limited, Sus-
sex, UK) [24, 25]. The AFP assays were performed at the
Biochemistry Department at Birmingham Women’s Hos-
pital (Perkin Elmer Wallac Oy, Turku, Finland) after a
single freeze-thaw cycle. The laboratories are CPA (UK)
Ltd. accredited and are externally quality assessed by
NEQAS and Down’s syndrome Quality Assurance Sup-
port Service (DQASS). The inter-assay and intra-assay
coefficient of variation for measured serum AFP, sFlt-1,
and PlGF were all < 5%.
Adjustment for standard prognostic factors
Results were analysed on their original scale, as opposed
to multiples of the median (MoMs), as all centres used
the same method of measurement. Some researchers
prefer using MoMs to deal with different measurements
and case mix in each centre, but concerns have been
raised [26]. Here, all centres used the same measurement
method, and we adjusted for case mix via standard prog-
nostic factors. Multivariable analyses were adjusted for
standard clinical information considered to be standard
prognostic factors: maternal BMI, age, smoking status,
ethnicity, parity, and mode of conception (Table 1). The
neonatal outcome was also adjusted for gestational age
at delivery and steroid and antenatal magnesium
sulphate administration. It was not possible to adjust for
gestational age at blood sampling as gestational age was
calculated based on CRL which is one of the potential
prognostic factors under evaluation.
Outcomes
There is no internationally agreed core outcome set for
twin pregnancies; therefore, outcomes were formulated
by our research team. The primary outcome of our study
was a fetal adverse outcome composite defined as at
least one of the following: TTTS, antenatally detected
growth restriction, postnatally detected growth restric-
tion, twin anaemia polycythaemia sequence (TAPS), twin
oligohydramnios-polyhydramnios sequence (TOPS) or
intrauterine fetal death (IUFD) (Additional file 1). We also
examined individual complications as secondary outcomes:
(a) TTTS: defined and staged as per Quintero criteria
[27]. Pregnancies affected by TTTS with concurrent
Table 1 Maternal characteristics used as adjustment factors
Fetal composite (TTTS, TAPS, TOPS, IUGR,
IUFD)
At least one fetal
complication present
(n = 94)
No fetal
complication
(n = 83)
Maternal age, mean (SD) years 30.73 (5.30) 29.99 (5.53)
Maternal BMI, mean (SD) kg/m2 24.71 (5.08) 25.05 (5.77)
Maternal smoking status, n (%)
Never 64 (75.29) 63 (79.75)
Current smoker 8 (9.41) 4 (5.06)
Ex-smoker 13 (15.29) 12 (15.19)
Maternal ethnicity, n (%)
White 60 (64.52) 52 (65.00)
Mixed 3 (3.23) 7 (8.75)
Oriental 11 (11.83) 11 (13.75)
South Asian 12 (12.90) 7 (8.75)
African-Caribbean 7 (7.53) 3 (3.75)
Parity, n (%)
0 61 (64.89) 46 (55.42)
1 23 (24.47) 25 (30.12)
2 8 (8.51) 10 (12.05)
3 1 (1.06) 1 (1.20)
4 1 (1.06) 1 (1.20)
Assisted conception, n (%) 14 (15.22) 10 (12.50)
Gestational age at delivery,
median (IQR)
34.36 (30.00, 36.43) 36.00 (35.00, 36.57)
Steroids administration 67 (71.28) 58 (70.73)
Magnesium sulphate
administration
10 (10.64) 2 (2.44)
BMI body mass index, IUFD intrauterine fetal death, IUGR intrauterine growth
restriction, TAPS twin anaemia polycythaemia sequence, TOPS twin
oligohydramnios-polyhydramnios sequence, TTTS twin-twin
transfusion syndrome
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growth restriction were not included in the
antenatal or postnatally detected growth restriction
groups
(b) Antenatally detected fetal growth restriction:
abdominal circumference (AC) or estimated fetal
weight (EFW) < 10th centile in either/both fetus(es)
and/or growth discordance > 20% recorded at least
twice over ≥ 2-week period
(c) Postnatally detected growth restriction: birthweight
< 9th centile on the World Health Organization
Growth Charts [28]
(d) IUFD: sub-classified as either single IUFD (sIUFD)
or double IUFD (dIUFD). The pregnancy was con-
sidered a miscarriage if the pregnancy loss occurred
at 14–24 weeks and a stillbirth if ≥ 24 weeks
(e) Spontaneous preterm birth (PTB): between 24 and
34 weeks gestation. Iatrogenic PTB delivery was not
included
(f ) Neonatal composite outcome: see Additional file 1
(g) Maternal composite outcome: see Additional file 1
Statistical analysis
All analyses were performed using Stata/MP 14.0 (Stata
Corporation, TX, USA). If > 5% data were missing (19%
for maternal BMI and 7% for smoking status), multiple
imputation was performed to replace the missing values
using a chained equation approach, with predictive mean
matching for continuous variables, based on the existing
and potential prognostic factors and fetal adverse out-
come composite outcome [29, 30]. Ten imputed datasets
were created and results were combined across all data-
sets using Rubin’s rules to obtain final model estimates
[31]. The neonatal outcome was missing for 14 babies,
but the missing data were not imputed.
For each of the primary and secondary outcomes, uni-
variable logistic regression models were fitted, calculat-
ing the unadjusted odds ratio (95% confidence interval)
for the association between each potential prognostic
factor and each outcome. Multivariable logistic regres-
sion models were then used to estimate the independent
prognostic value (i.e. adjusted odds ratio (aOR) and its
95% confidence interval) of each potential prognostic
factor after adjusting for standard prognostic character-
istics defined a priori: maternal booking BMI, age, smok-
ing status, ethnicity, parity, and mode of conception.
The p value is also presented for the aOR. To gauge the
potential increase in discrimination performance of a
prognostic model that includes each potential prognostic
factor in addition to existing factors, the change in ap-
parent c-statistic (increase in area under the curve) for
each outcome was calculated (i.e. difference in apparent
c-statistic for models with standard characteristics includ-
ing or excluding each factor). No adjustment for potential
model overfitting was made during the calculation, as this
was only for illustration of the potential impact of includ-
ing the factors.
For outcomes relating to individual babies, a random
intercept term at the level of the mother was included to
account for clustering of multiple babies per mother.
The clustering of babies within mothers for the outcome
of IUFD was not able to be accounted for using a ran-
dom effects model due to small numbers and minimal
variation within the clusters which created convergence
issues; hence, a fixed effect model was used. Clustering
by hospital was also adjusted by putting a random effect
on the intercept which allowed for heterogeneity in
baseline risk across hospitals.
The serum biomarkers were log transformed as they
were highly skewed. Continuous prognostic factors were
included in the models as linear terms. Non-linear terms
were considered by using fractional polynomials [32];
however, the best fitting models were those including a
linear term only.
Translating the prognostic effects into absolute risk
To translate how the absolute risk of developing the fetal
adverse outcome might change across the distribution of
each potential prognostic factor, two values for each po-
tential prognostic factor were chosen a priori. The values
for the ultrasound measurements were based on cut-offs
used in existing literature for NT % discordance (0% and
20%) and CRL % discordance (0% and 10%). The values
used for the maternal serum biomarkers were based on
centiles in the study cohort: for AFP and sFlt-1, the 50th
centile and 95th centile were used, and for PlGF, the
50th and 5th centile were used. For each of these values,
absolute risk was estimated from the final model with
other variables in the model given the mean values in
the study cohort: 30 years old, BMI 25, non-smoker,
Caucasian, nulliparous, and natural conception.
Results
Patient characteristics
One hundred seventy-seven MCDA twin pregnancies
(354 fetuses) were identified and included in the study.
The mean age of the participants was 30.4 years (SD
5.4), and mean BMI was 24.9 kg/m2 (SD 5.4). The major-
ity of women had never smoked (77.4%), 60.5% were
nulliparous, and most conceived spontaneously (86.0%).
The maternal characteristics are summarised in Table 1.
The median gestational age at blood sampling was 12 +
6 weeks (IQR 12 + 3, 13 + 2). The median values of the po-
tential prognostic factors in the cohort were inter-twin
NT discordance 11.8% (IQR 6.6, 21.2), inter-twin CRL dis-
cordance 4.2% (IQR 1.7, 7.0), AFP 29.3 U/mL (IQR 23.4,
41.5), sFlt-1 2163 pg/mL (IQR 1645, 2945.5), and PlGF
60.5 pg/mL (IQR 40.9, 89.0).
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Thirty-one percent experienced no adverse outcome
and resulted in two healthy live births after 34 weeks of
gestation (Table 2). Over half of the cohort (53.1%) had
a pregnancy affected by at least one adverse outcome in
the ‘fetal adverse outcome composite’. TTTS occurred
in 13.0%, which presented at a median gestational age of
18 + 1 weeks (IQR 18, 24); the median Quintero stage
was III, with 69% Quintero stage > II at presentation.
Fifty-five percent of those with postnatally detected
growth restriction were not identified antenatally. A sub-
stantial proportion of those with a sIUFD/dIUFD was
complicated by TTTS: 63.6% (7/11) and 58.3% (7/12) re-
spectively. Antenatal growth restriction affected 2/11
sIUFDs and 3/12 dIUFDs. There were two cases of
TAPS, and no cases of TOPS.
A quarter of pregnancies (26.0%) had at least one ma-
ternal complication, the most common complication be-
ing gestational diabetes (13.6%). There were severe
complications of hypertensive disorders of pregnancy in
7.9%. Two cases were complicated by placental abrup-
tion (1.1%) and 7 (4.0%) pregnancies were complicated
by massive obstetric haemorrhage. Three mothers devel-
oped renal or liver dysfunction (1.7%). In total, five
(2.8%) needed admission to high-dependency or inten-
sive care unit. There were no maternal deaths.
Primary outcome
Fetal adverse outcome composite
There was a statistically significant unadjusted associ-
ation between increased odds of fetal adverse outcome
composite and increased inter-twin NT% discordance
and increased CRL% discordance in the first trimester
(Table 3). These associations remained after adjustment,
demonstrating that these factors have independent prog-
nostic value toward the fetal adverse outcome compos-
ite, with an estimated 3% (aOR 1.03 [95%CI 1.01, 1.06],
p = 0.01) increase in the odds of experiencing an out-
come in the fetal adverse outcome composite, for each
1% increase in NT discordance, and an estimated 17%
(aOR 1.17 [95%CI 1.07, 1.29], p = 0.001) increase in the
odds of experiencing an outcome in the fetal adverse
outcome composite, for each 1% increase in CRL dis-
cordance. The baseline c-statistic (for the model includ-
ing only standard characteristics) was 0.594, and the
increase in the c-statistic when each prognostic factor
was additionally included was quite high with the NT%
discordance having an increase in the c-statistic of 0.045
and CRL% discordance 0.103. There were no statistically
significant associations between any of the maternal
serum biomarkers (AFP, PlGF, or sFLT-1) measured in
the first trimester and subsequent fetal adverse outcome
(as measured by the composite), though confidence in-
tervals were wide.
Secondary outcomes
Twin-twin transfusion syndrome (TTTS)
Increased first-trimester inter-twin NT% discordance
was associated with development of TTTS after adjust-
ment for previously standard prognostic factors (aOR
1.06 [95%CI 1.03, 1.10], p < 0.001) with a 6% increase in
the odds of developing TTTS, for each 1% increase in
NT discordance (Table 3). Increased maternal serum
AFP measured in the first trimester was associated with
the development of TTTS before adjustment (OR 3.04
[95%CI 1.05, 8.78]). After adjustment for previously
identified prognostic factors, this was no longer statisti-
cally significant (aOR 3.24 [95%CI 1.00, 10.48], p =
0.050); however, the majority of the confidence interval
suggests a prognostic effect, although with large uncer-
tainty about the magnitude. Decreased maternal serum
PlGF measured in the first trimester was associated with
the development of TTTS before adjustment (OR 0.43
[95%CI 0.20, 0.91]), and this remained after adjustment
for previously identified prognostic factors (aOR 0.42
[95%CI 0.19, 0.93], p = 0.03), demonstrating an estimated
42% increase in the odds of TTTS for each concentra-
tion unit decrease in loge-PlGF. The baseline c-statistic
(for the model with only standard prognostic character-
istics) was 0.617, and the increase in the c-statistic when
each prognostic factor was included was quite high for
NT (0.137), AFP (0.067), and PlGF (0.074), respectively.
Antenatally detected growth restriction
Increased first-trimester inter-twin CRL% discordance
was an independent prognostic factor for antenatally
Table 2 Number of events (per pregnancy (n = 177) unless
otherwise stated)
N (%)
Uncomplicated monochorionic diamniotic twin
pregnancy, delivered > 34 weeks gestation
55/177 (31.07)
Fetal composite* 94/177 (53.11)
Twin-twin transfusion syndrome 23/177 (12.99)
Antenatal growth restriction 41/177 (23.16)
Antenatal growth restriction (per fetus) 73/354 (20.6)
Postnatal growth restriction 43/177 (24.29)
Postnatal growth restriction (per baby) 54/354 (15.25)
Intrauterine fetal death (single) 11/177 (6.21)
Intrauterine fetal death (double) 12/177 (6.78)
Maternal antenatal and postnatal composite ** 46/177 (25.99)
Spontaneous preterm birth at 24–34 weeks 12/177 (6.78)
Neonatal composite ** 91/340 (26.76)
*Fetal composite included at least one of the following: twin-twin transfusion
syndrome, antenatally detected growth restriction, postnatally detected
growth restriction, twin anaemia polycythaemia sequence, or intrauterine
fetal death
**see Additional file 1 for full definitions of these composites
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detected growth restriction (aOR 1.20 [95%CI 1.08,
1.34], p = 0.001) (Table 3). No other first-trimester fetal
ultrasound or maternal biomarker measurements were
associated with antenatally detected growth restriction.
The baseline c-statistic was 0.616 (for the model with
only standard prognostic characteristics).
Intrauterine fetal death (IUFD)
The majority of the IUFDs were associated with TTTS and/
or antenatally detected growth restriction (78%). It was not
possible to separate spontaneous IUFDs from those
associated with TTTS or growth restriction as the cohort
numbers were too small. The only statistically significant
maternal serum biomarker was decreased PlGF which
was a prognostic factor for sIUFD (aOR 0.34 [95% CI 0.12,
0.98], p = 0.045) and dIUFD (aOR 0.18 [95% CI 0.05, 0.58],
p = 0.005) (Table 3). No other prognostic factors were found
in the ultrasound measurements or serum biomarkers for
the other outcomes, including maternal and neonatal out-
comes (Additional file 2). The baseline c-statistic was 0.625
and 0.783 for sIUFD and dIUFD respectively (for the model
with only standard prognostic characteristics).
Table 3 Association between potential prognostic factors and outcome (n = 177 pregnancies)
Potential prognostic factor Unadjusted OR (95%CI) Adjusted* OR (95%CI) p value Change in c-statistic†
Fetal adverse outcome composite
NT (% discordance) 1.03 (1.01, 1.05) 1.03 (1.01, 1.06) 0.011 0.045
CRL (% discordance) 1.16 (1.06, 1.27) 1.17 (1.07, 1.29) 0.001 0.103
AFP 1.91 (0.93, 3.94) 2.08 (0.94, 4.59) 0.071 0.026
sFlt-1 1.12 (0.52, 2.40) 1.03 (0.42, 2.50) 0.950 < 0.001
PlGF 0.73 (0.44, 1.22) 0.65 (0.37, 1.13) 0.125 0.014
Twin-twin transfusion syndrome (TTTS)
NT (% discordance) 1.05 (1.02, 1.08) 1.06 (1.03, 1.10) < 0.001 0.137
CRL (% discordance) 1.07 (0.96, 1.20) 1.09 (0.97, 1.23) 0.161 0.032
AFP 3.04 (1.05, 8.78) 3.24 (1.00, 10.48) 0.050 0.067
sFlt-1 1.91 (0.62, 5.88) 1.64 (0.44, 6.03) 0.459 0.006
PlGF 0.43 (0.20, 0.91) 0.42 (0.19, 0.93) 0.032 0.074
Antenatal growth restriction
NT (% discordance) 1.01 (0.99, 1.03) 1.01 (0.99, 1.04) 0.261 0.014
CRL (% discordance) 1.17 (1.06, 1.30) 1.20 (1.08, 1.34) 0.001 0.119
AFP 1.55 (0.67, 3.55) 2.10 (0.82, 5.40) 0.123 0.032
sFlt-1 1.25 (0.50, 3.13) 1.47 (0.49, 4.35) 0.491 0.011
PlGF 0.91 (0.50, 1.66) 0.88 (0.44, 1.76) 0.720 −0.001
Single intrauterine fetal death (sIUFD)
NT (% discordance) 1.01 (0.98, 1.05) 1.02 (0.98, 1.06) 0.425 <−0.001
CRL (% discordance) 1.17 (1.00, 1.36) 1.19 (1.01, 1.40) 0.035 0.085
AFP 0.68 (0.16, 2.87) 0.80 (0.17, 3.90) 0.787 −0.004
sFlt-1 1.27 (0.27, 6.04) 1.79 (0.30, 10.64) 0.523 <−0.001
PlGF 0.35 (0.13, 0.97) 0.34 (0.12, 0.98) 0.045 0.057
Double intrauterine fetal death (dIUFD)
NT (% discordance) 1.02 (0.98, 1.06) 1.02 (0.98, 1.06) 0.420 −0.005
CRL (% discordance) 1.06 (0.91, 1.24) 1.12 (0.94, 1.33) 0.221 0.019
AFP 1.33 (0.34, 5.21) 0.97 (0.18, 5.33) 0.970 <−0.001
sFlt-1 4.13 (0.92, 18.58) 8.21 (1.02, 66.24) 0.048 0.035
PlGF 0.23 (0.08, 0.63) 0.18 (0.05, 0.58) 0.005 0.080
The AFP, sFlt-1, and PlGF are loge transformed
*Adjusted for maternal BMI, age, smoking status, ethnicity, parity, and mode of conception. sIUFD and dIUFD were only able to be adjusted for maternal BMI, age,
ethnicity, and mode of conception. Italics denote significant associations. P value is related to the adjusted OR
†Change in c-statistic represents the additional prognostic value of each individual potential prognostic factor above the standard prognostic factors (maternal
BMI, age, smoking status, ethnicity, parity, and mode of conception). The baseline c-statistics for the fetal adverse outcome composite is 0.594, TTTS is 0.617,
antenatal growth restriction is 0.616, sIUFD is 0.625, and dIUFD is 0.783
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Translating the prognostic effects into absolute risk
The odds of developing the fetal adverse outcome based
on two values for each potential prognostic factor were
translated to absolute risks, to demonstrate how the esti-
mated prognostic effect for each individual factor might
change absolute risk predictions, if a prognostic model
were developed in the future. Predicted outcome risk is
shown for various values of each factor and for individ-
uals whose other standard prognostic factors are set at
the mean in the dataset (Table 4). No adjustment for po-
tential model overfitting was made, as this was only for
illustration of the potential impact of the included fac-
tors on predicted risks from a prognostic model.
Discussion
Main findings
Increasing percentage difference in NT and CRL was
statistically significantly associated with our fetal adverse
outcome composite, including after adjustment for
standard prognostic factors defined by maternal vari-
ables. Increasing inter-twin CRL discordance was also
statistically significantly associated with IUFD and ante-
natally detected growth restriction, whilst an increasing
discordance in inter-twin NT was statistically signifi-
cantly associated with the development of TTTS. When
the association was considered at an individual level in
clinical scenarios, there was a potential clinical utility of
individual biomarkers.
Strengths and limitations
Our study has the benefit of investigating the prognostic
values of inter-twin NT and CRL percentage discordance as
a continuous variable whereas other studies dichotomised
the data using non-validated ‘cut-offs of abnormality’ which
loses important information (often equivalent to throwing
away one third of the data) [33].
When evaluating maternal serum biomarkers in our
study, neither serum AFP, PlGF, nor sFlt-1 measured be-
tween 11 + 0 and 13 + 6 weeks was prognostic for the
fetal adverse outcome composite. However, unadjusted
logistic regression indicated that both AFP and PlGF
were significantly associated with the development of
TTTS. On adjusting for existing standard prognostic fac-
tor, the association persisted for PlGF and approached
significance for AFP. These findings are slightly different
to our previous findings that second-trimester maternal
serum AFP and sFlt-1 to PlGF ratio are significantly ele-
vated in MC twin pregnancies complicated by TTTS
compared to uncomplicated MC twin pregnancies; how-
ever, this was when signs of TTTS were already apparent
and the condition had been diagnosed [16, 17].
This study is the first that an association between
first-trimester maternal serum AFP and PlGF and the
adverse outcome has been noted, and it should be
emphasised that this association is prior to the develop-
ment of clinical TTTS. We did this using widely utilised
and validated methodologies used in accredited bio-
chemistry laboratories. In our cohort study, sIUFD and
dIUFD occurred in pregnancies affected by TTTS in a
substantial number of cases; thus, it is possible that the
secondary outcome of IUFD was associated with the
presence of TTTS. This is an interesting finding and it
may be that PlGF could be used as a marker of severity
of TTTS, although this does need further investigation
and was not the aim of this study. The exact mecha-
nisms for the development of TTTS are complex. The
association between TTTS and decreased PlGF may be
biologically plausible as PlGF is pro-vasculogenic and
pro-angiogenic [34] and TTTS is related to the forma-
tion of inter-twin placental anastomoses. The border-
line association with increased AFP warrants further
investigation as it is a marker of placental function [35],
and although we previously found a significant increase
in second-trimester maternal serum from TTTS preg-
nancies [16], another study found no difference [36].
The limitations of this study are that it is retrospective
and the cohort size is relatively small. For the maternal
biomarkers, the confidence intervals surrounding the
corresponding odds ratios are large, meaning the esti-
mates are not very precise. Hence, this large variability
needs to be investigated in further research with larger
sample sizes, allowing the assessment of multiple prog-
nostic factors in combination. This could enable the de-
velopment of a prognostic model, depending on the
predictive ability. The other important consideration is
that although there is a call for universal definitions of
outcome in MC twin pregnancies [37], this is not yet
internationally agreed. This is particularly true for
Table 4 Predicted risk of developing a fetal adverse outcome
according to potential prognostic factor measurements
determined a priori
Potential prognostic factor measurement Predicted risk*
NT (% discordance) 0% 0.446
NT (% discordance) 20% 0.604
CRL (% discordance) 0% 0.379
CRL (% discordance) 10% 0.750
AFP 50th centile (29.3 U/mL) 0.549
AFP 95th centile (54.7 U/mL) 0.658
PlGF 50th centile (60.4 pg/mL) 0.535
PlGF 5th centile (23.6 U/mL) 0.634
sFlt-1 50th centile (2169 pg/mL) 0.545
sFlt-1 95th centile (4089 pg/mL) 0.549
*Risk predictions obtained from the fitted multivariable model for values
shown and using the mean values of the standard factors included in the
model: 30 years old, BMI 25, non-smoker, Caucasian, nulliparous, and
natural conception
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TTTS and antenatal fetal growth restriction in MC
twins. Recently, a Delphi consensus was published to
focus definitions and outcomes in fetal growth restric-
tion in twins [38], but this requires validation. Thus, we
chose fetal adverse outcome composite as an endpoint,
as well as individual pathologies reported in MC twin
pregnancies. Although we were as pragmatic as possible
with the growth restriction definitions, different patho-
physiological mechanisms [39] may be included as the
sample size was too small to do further sub-group ana-
lysis, possibly explaining why biomarkers were not sig-
nificant for the growth restriction outcomes. It may
also be that “true” or “confirmed” growth restriction
was not represented due to the discrepancy between
antenatally and postnatally detected growth restriction
not being concordant, although the growth restriction
definitions were chosen as the antenatal measurements
are those that guide clinicians management decisions.
However, our analysis was performed according to ro-
bust prognostic methodology and has been reported in
keeping with the REporting recommendations for
tumor MARKer prognostic studies (REMARK) [40].
Interpretation
The aim of this work was to evaluate the prognostic
ability of individual first-trimester markers for adverse
outcome in MC twins. For those markers where there
was a statistically significant independent association
with adverse outcome, calculating the absolute risk for
each outcome using common values demonstrated that
the markers may be useful clinically, although this de-
pends on the change in management.
A recent systematic review by Stagnati [15] sum-
marised the results of seven studies comprising 1087
MC twin pregnancies. These studies defined discord-
ant NT in various ways: > 10%, > 20%, or a difference
of > 0.5 or 0.6 mm. Of the MC twins, 128 developed
TTTS, the only adverse outcome examined. The
meta-analysis demonstrated that NT% discordance
and NT> 95th centile had a prognostic association
with the development of TTTS: positive likelihood ra-
tio (LR+) 1.92 [95%CI 1.25, 2.96] and negative likeli-
hood ratio (LR−) 0.65 [95% CI 0.50, 0.84] and LR+
2.63 [95%CI, 1.51, 4.58] and LR− 0.85 [95% CI, 0.75,
0.96], respectively. However, overall the ‘pooled data’
demonstrated a low sensitivity (52.8% [95% CI 43.8,
61.7]; I2 = 48.7%) and specificity (72.5% [95% CI 61.7],
82.0; I2 = 84.3%) for detecting TTTS. Our work has
examined the biomarkers as continuous variables, to
ensure that no prognostic ability is lost by choosing
an arbitrary threshold, but has demonstrated a similar
association with adverse outcome but limited transla-
tion for individual biomarkers into a clinically useful
predictive tool.
Conclusions
Currently, there are no established prognostic models for
predicting adverse outcome in MC twins. This study has
identified potential individual prognostic factors in the
first trimester (fetal biometric and maternal serum bio-
markers) that show promise but require further robust
evaluation in a larger, prospective series of MC twin preg-
nancies, so that their usefulness both individually and in
combination can be defined [9]. When larger datasets are
available, these markers could potentially be combined
with standard prognostic variables to form a prognostic
model ready for internal and external validation.
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